A recent study suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who stop traditional diet and exercise programs.
Published data in a leading health publication points out that while obese people can lose substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users using such drugs need to be informed of the danger of rapid rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to starting mass in about a year and a half.
Comparing Approaches
The research, which reviewed dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
The team point out that individuals who lose weight through lifestyle changes alone typically experience a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Regain
Experts suggest the way of the drugs is key to understanding the accelerated regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the system to produce less of its own natural hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in appetite is uncontrolled, making binge eating a significant risk."
An Ongoing Condition?
The NHS recommend the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the high risk of relapse, the therapy should be considered long-term.
This opinion is reinforced by drug manufacturers, who state that the findings "underscore the chronic character of obesity," comparing it to managing conditions like high blood pressure.
User Testimonies
Users who have discontinued the medication report a intense return of cravings.
"I experienced a switch flipping and you become ravenous," recalled an individual.
The struggle is worsened if users have not established lasting lifestyle or habit modifications during treatment.
Significant Interest
Recent estimates show that millions of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is more common among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent solution and maintained weight loss hinges on ongoing behavioural changes.
